



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum

Citation for published version:

Soch, J, Richter, A, Kizilirmak, JM, Schütze, H, Ziegler, G, Altenstein, S, Brosseron, F, Dechent, P, Fliessbach, K, Freiesleben, SD, Glanz, W, Gref, D, Heneka, MT, Hetzer, S, Incesoy, EI, Kilimann, I, Kimmich, O, Kleinedam, L, Kuhn, E, Laske, C, Lohse, A, Lüsebrink, F, Munk, MH, Peters, O, Preis, L, Priller, J, Ramirez, A, Roeske, S, Rostamzadeh, A, Roy-Kluth, N, Scheffler, K, Schmid, M, Schneider, A, Spottke, A, Spruth, EJ, Teipel, S, Wiltfang, J, Jessen, F, Wagner, M, Düzel, E & Schott, BH 2024, 'Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum', *Brain*.
<https://doi.org/10.1093/brain/awae149>

Digital Object Identifier (DOI):

[10.1093/brain/awae149](https://doi.org/10.1093/brain/awae149)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Brain

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 **Single-value brain activity scores reflect both severity and** 2 **risk across the Alzheimer's continuum**

3 Joram Soch,^{1,2,3} Anni Richter,^{4,5,6} Jasmin M. Kizilirmak,^{1,7} Hartmut Schütze,^{8,9} Gabriel Ziegler,^{8,9}
4 Slawek Altenstein,^{10,11} Frederic Brosseron,¹² Peter Dechent,¹³ Klaus Fliessbach,^{12,14} Silka Dawn
5 Freiesleben,^{10,11} Wenzel Glanz,⁸ Daria Gref,¹¹ Michael T. Heneka,¹⁵ Stefan Hetzer,¹⁶ Enise I.
6 Incesoy,^{8,9,17} Ingo Kilimann,^{18,19} Okka Kimmich,¹² Luca Kleineidam,^{12,14} Elizabeth Kuhn,¹²
7 Christoph Laske,^{20,21} Andrea Lohse,¹¹ Falk Lüsebrink,⁸ Matthias H. Munk,^{20,22} Oliver Peters,^{10,11}
8 Lukas Preis,¹¹ Josef Priller,^{10,11,23,24} Alfredo Ramirez,^{12,14,25,26,27} Sandra Roeske,¹² Ayda
9 Rostamzadeh,²⁸ Nina Roy-Kluth,¹² Klaus Scheffler,²⁹ Matthias Schmid,^{12,30} Anja Schneider,^{12,14}
10 Annika Spottke,^{12,31} Eike Jakob Spruth,^{10,11} Stefan Teipel,^{18,19} Jens Wiltfang,^{1,32,33} Frank
11 Jessen,^{12,25,28} Michael Wagner,^{12,14} Emrah Düzel^{8,9} and Björn H. Schott^{1,4,32,34}

12 **Abstract**

13 Single-value scores reflecting the deviation from (FADE score) or similarity with (SAME score)
14 prototypical novelty-related and memory-related functional magnetic resonance imaging (fMRI)
15 activation patterns in young adults have been proposed as imaging biomarkers of healthy
16 neurocognitive aging. Here, we tested the utility of these scores as potential diagnostic and
17 prognostic markers in Alzheimer's disease (AD) and risk states like mild cognitive impairment
18 (MCI) or subjective cognitive decline (SCD).

19 To this end, we analyzed subsequent memory fMRI data from individuals with SCD, MCI, and
20 AD dementia as well as healthy controls (HC) and first-degree relatives of AD dementia patients
21 (AD-rel) who participated in the multi-center DELCODE study (N = 468). Based on the
22 individual participants' whole-brain fMRI novelty and subsequent memory responses, we
23 calculated the FADE and SAME scores and assessed their association with AD risk stage,
24 neuropsychological test scores, CSF amyloid positivity, and ApoE genotype.

25 Memory-based FADE and SAME scores showed a considerably larger deviation from a
26 reference sample of young adults in the MCI and AD dementia groups compared to HC, SCD

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site; for further information please contact journals.permissions@oup.com.

1 and AD-rel. In addition, novelty-based scores significantly differed between the MCI and AD
2 dementia groups. Across the entire sample, single-value scores correlated with
3 neuropsychological test performance. The novelty-based SAME score further differed between
4 A β -positive and A β -negative individuals in SCD and AD-rel, and between ApoE ϵ 4 carriers and
5 non-carriers in AD-rel.

6 Hence, FADE and SAME scores are associated with both cognitive performance and individual
7 risk factors for AD. Their potential utility as diagnostic and prognostic biomarkers warrants
8 further exploration, particularly in individuals with SCD and healthy relatives of AD dementia
9 patients.

10

11 **Author affiliations:**

12 1 German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany

13 2 Bernstein Center for Computational Neuroscience (BCCN), 10117 Berlin, Germany

14 3 Max Planck Institute for Human Cognitive and Brain Sciences (MPI CBS), Leipzig, Germany

15 4 Leibniz Institute for Neurobiology (LIN), 39118 Magdeburg, Germany

16 5 German Center for Mental Health (DZPG), partner site Halle-Jena-Magdeburg, 39120
17 Magdeburg, Germany

18 6 Center for Intervention and Research on adaptive and maladaptive brain Circuits underlying
19 mental health (C-I-R-C), Halle-Jena-Magdeburg, 39120 Magdeburg, Germany

20 7 German Center for Higher Education Research and Science Studies (DZHW), 30159
21 Hannover, Germany

22 8 German Center for Neurodegenerative Diseases (DZNE), 39120 Magdeburg, Germany

23 9 Institute of Cognitive Neurology and Dementia Research (IKND), Otto von Guericke
24 University, 39120 Magdeburg, Germany

25 10 German Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany

1 11 Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate
2 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
3 Health, 10117 Berlin, Germany

4 12 German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127
5 Bonn, Germany

6 13 MR-Research in Neurosciences, Department of Cognitive Neurology, Georg August
7 University, 37075 Göttingen, Germany

8 14 Department of Neurodegenerative Disease and Geriatric Psychiatry, University of Bonn
9 Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany

10 15 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 4367
11 Belvaux, Luxembourg

12 16 Berlin Center for Advanced Neuroimaging, Charité – Universitätsmedizin Berlin, corporate
13 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
14 Health, 10117 Berlin, Germany

15 17 Department for Psychiatry and Psychotherapy, University Clinic Magdeburg, 39120
16 Magdeburg, Germany

17 18 German Center for Neurodegenerative Diseases (DZNE), 18147 Rostock, Germany

18 19 Department of Psychosomatic Medicine, Rostock University Medical Center, 18147 Rostock,
19 Germany

20 20 German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany

21 21 Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department
22 of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen, Germany

23 22 Department of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen,
24 Germany

25 23 School of Medicine, Department of Psychiatry and Psychotherapy, Technical University of
26 Munich, 81675 Munich, Germany

27 24 University of Edinburgh and UK DRI, Edinburgh EH16 4SB, UK

1 25 Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),
2 University of Cologne, 50931 Köln, Germany

3 26 Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and
4 Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne,
5 50924 Cologne, Germany

6 27 Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative
7 Diseases, San Antonio, TX 78229, USA

8 28 Department of Psychiatry, University of Cologne, Medical Faculty, 50924 Cologne, Germany

9 29 Department for Biomedical Magnetic Resonance, University of Tübingen, 72076 Tübingen,
10 Germany

11 30 Institute for Medical Biometry, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn,
12 Germany

13 31 Department of Neurology, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany

14 32 Department of Psychiatry and Psychotherapy, University Medical Center, 37075 Göttingen,
15 Germany

16 33 Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of
17 Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal

18 34 Center for Behavioral Brain Sciences (CBBS), 39106 Magdeburg, Germany

19

20 Correspondence to: PD Dr, Dr Björn Hendrik Schott

21 Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, 37075
22 Göttingen, Germany

23 E-mail: bjoernhendrik.schott@med.uni-goettingen.de; bjoern-hendrik.schott@dzne.de

24

25 **Running title:** Functional MRI scores in Alzheimer's disease

26 **Keywords:** Alzheimer's disease; mild cognitive impairment; novelty processing; subsequent
27 memory; fMRI scores; dementia risk

1 Introduction

2 Cognitive decline and brain structural changes occur in most humans during aging, including in
3 healthy individuals¹⁻³. Explicit, and particularly, episodic memory, the ability to store, maintain,
4 and retrieve single events⁴, is especially vulnerable to age-related decline, particularly in
5 individuals at risk for Alzheimer's disease (AD)⁵⁻⁸. However, inter-individual variability is high⁹,
6 and distinguishing accelerated, but yet for-age normal cognitive decline from pre-clinical AD is
7 challenging.

8 Mild cognitive impairment (MCI), defined as measurable cognitive decline with preserved
9 functioning in activities of daily living^{10,11}, is a well-characterized risk state for AD. Recently,
10 subjective cognitive decline (SCD), defined by worry about deteriorating cognitive function
11 despite normal performance, has been identified as a pre-MCI risk state^{12,13}. Despite an increased
12 risk of developing AD dementia compared to the general population, not all individuals with
13 MCI and even fewer with SCD progress to dementia. Therefore, the establishment of biomarkers
14 reflecting an individual's risk for AD dementia is highly desirable¹⁴⁻¹⁷.

15 Currently, *loco typico* brain structural changes in AD have yielded several neuroimaging
16 biomarkers for AD, including reduced gray matter volume (GMV)^{18,19}, reduced hippocampal
17 volumes²⁰, and white matter lesion load^{21,17}. Moreover, memory-related functional magnetic
18 resonance imaging (fMRI) may constitute a helpful measure for differentiating normal from at-
19 risk neurocognitive aging²²⁻²⁵.

20 In the commonly employed subsequent memory paradigm, participants encode stimuli, which
21 they are subsequently asked to recall or recognize. Successful encoding, assessed via comparison
22 of subsequently remembered vs. forgotten items (i.e., subsequent memory effect), typically
23 elicits increased activations of the bilateral medial temporal lobe (MTL), including the
24 hippocampus, as well as inferior temporal, parieto-occipital and prefrontal cortices (for meta-
25 analyses, see ^{25,26}). Presenting pre-familiarized stimuli intermixed with novel stimuli during
26 encoding additionally allows the study of novelty effects (i.e., novel vs. familiar items^{27,22}),
27 which typically encompass activations in MTL regions and deactivations of default mode
28 network (DMN) regions like the precuneus²⁸⁻³⁰.

1 Despite the relatively large number of studies on memory encoding in AD and MCI (for meta-
2 analyses, see ³¹⁻³⁴), only few studies have reported actual subsequent memory effects³⁵⁻³⁷.
3 Instead, most studies report on encoding compared to a low-level baseline or on novelty
4 effects^{31,34,24}. One reason for this may be that poor episodic memory in AD, and to some extent
5 in MCI, reduces the signal-to-noise ratio of encoding-specific fMRI responses, making it
6 difficult to differentiate between subsequently remembered and forgotten items. Compatibly, we
7 have recently shown that, when comparing first-level fMRI models using Bayesian model
8 selection, memory-invariant fMRI models provide a better fit than subsequent memory models in
9 individuals with MCI or mild AD dementia³⁸.

10 In previous studies investigating healthy older adults^{22,29,30,39}, single-value scores extracted from
11 whole-brain fMRI contrast maps for novelty processing and subsequent memory have been
12 proposed as potential biomarkers of neurocognitive aging. Single-value scores quantify
13 *Functional Activity Deviation during Encoding* (FADE) or *Similarity of Activations during*
14 *Memory Encoding* (SAME) in relation to prototypical activations in young adults. Thus, these
15 scores provide reductionist measures of an individual's memory network integrity. In a sample of
16 healthy young and older adults, we have previously reported that these scores differed between
17 age groups, correlated with memory performance^{39,30}, and were robust against potential
18 confounds like MRI scanner or reference sample²⁹.

19 Here, we investigated to what extent FADE and SAME reflect neurocognitive decline across the
20 AD risk spectrum. In addition to psychometric tests of memory performance and functional
21 neuroimaging, we examined the effects of the well-established ApoE genetic risk factor and of
22 the A β 42/40 ratio in cerebrospinal fluid (CSF)⁴⁰⁻⁴³. We applied our previously described
23 approach²⁹ to a large cohort from the DZNE Longitudinal Cognitive Impairment and Dementia
24 Study (DELCODE)⁴⁴, including healthy controls (HC), individuals with SCD, MCI, and mild
25 AD dementia, and first-degree relatives of AD dementia patients (AD-rel).

26 We hypothesized that FADE and SAME scores would be affected by clinical severity across the
27 AD risk spectrum, with increasing FADE scores (i.e., larger deviation from prototypical
28 activation patterns in a reference sample of young adults) and decreasing SAME scores (i.e.,
29 lower similarity with activation patterns in the reference sample). We further hypothesized that
30 (i) acquisition site, gender and educational status would not significantly affect the scores²⁹; (ii)

1 the scores would correlate with episodic memory performance and additional cognitive measures
2 across participant groups³⁰; and that (iii) ApoE ϵ 4 allele carriage and amyloid positivity (as
3 determined by the CSF A β 42/40 ratio), would be associated with higher FADE and lower SAME
4 scores within or across diagnostic groups.

5

6 **Materials and methods**

7 **Study cohort**

8 The study sample consisted of participants from the DELCODE Study
9 (<https://www.dzne.de/en/research/studies/clinical-studies/delcode/>)⁴⁴, including individuals with
10 SCD, MCI or early-stage AD as well as cognitively unimpaired older control participants and
11 healthy first-degree relatives of patients with AD dementia. DELCODE is a multi-center memory
12 clinic-based study focusing on preclinical stages of AD, conducted across different sites of the
13 German Center for Neurodegenerative Diseases (DZNE).

14 Complete baseline data (i.e., data from the first study visit) was available for 844 participants.
15 We excluded participants (i) without available diagnosis, (ii) missing or incomplete fMRI data,
16 and (iii) missing essential meta-data, resulting in a final sample size of N = 468 (HC: 128; SCD:
17 199; MCI: 74; AD: 21; AD-rel: 46). Participant demographics are reported in Table 1.

18

19 **Methods overview**

20 Apart from using a different study cohort, comprising five (HC, SCD, MCI, AD and AD-rel)
21 rather than two (healthy young and older adults) groups and the multi-centric acquisition, the
22 present study employed the same MRI acquisition parameters, fMRI processing pipeline and
23 analysis protocols as in ²⁹. The neuropsychological test batteries differed, owing to the
24 demographics and clinical characteristics of the study samples. All data analyses were performed
25 after publication of the reference study²⁹ (Table S2), following the approval of the analysis
26 protocol by the DELCODE steering committee. The corresponding data analysis proposal is
27 available from the authors upon request.

1 **Experimental paradigm**

2 Participants performed an adapted version of a previously described memory encoding task²² as
3 part of the DELCODE study protocol^{49,50}, which was also employed in our earlier study²⁹.
4 Briefly, participants viewed photographs of indoor and outdoor scenes, which were either novel
5 at the time of presentation (i.e., 44 indoor and 44 outdoor scenes) or repetitions of two pre-
6 familiarized “master” images (i.e., 22 indoor and 22 outdoor trials). In a recognition memory test
7 70 minutes later, participants were shown all novel images from the encoding session, now
8 considered “old” stimuli (88 images in total), and previously unseen, that is, “new” stimuli (44
9 images in total). Participants were asked to provide a recognition-confidence rating for each
10 image, using a five-point Likert scale ranging from “sure new” (1) over “don’t know” (3) to
11 “sure old” (5).

13 **MRI data acquisition**

14 MRI data were acquired at eight different sites across Germany using Siemens 3T MR
15 tomographs. All sites followed the DELCODE MRI protocol^{29,44,49}. Structural MRI included a
16 T1-weighted MPRAGE image (voxel size = 1 x 1 x 1 mm) and phase and magnitude fieldmaps
17 for later spatial artifact correction. Functional MRI consisted of 206 T2*-weighted echo-planar
18 images (EPIs; TR = 2.58 s, voxel size = 3.5 x 3.5 x 3.5 mm) acquired during the encoding
19 session of the memory task (09:01 min), and a resting-state session (180 scans, not used here).

21 **MRI data processing**

22 Data processing and analysis were performed using Statistical Parametric Mapping, version 12
23 (SPM12; Wellcome Centre for Human Neuroimaging, University College London, London, UK;
24 <https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) and in-house MATLAB scripts
25 (https://github.com/JoramSoch/FADE_SAME). Preprocessing of fMRI data included correction
26 for acquisition time (*slice timing*), head motion (*realignment*), and magnetic field
27 inhomogeneities using the fieldmaps (*unwarping*), coregistration of the T1-weighted MPRAGE
28 image to the mean EPI computed during realignment, segmentation of the coregistered

1 MPRAGE image, subsequent normalization of unwarped EPIs into the MNI standard space
2 (voxel size = 3 x 3 x 3 mm), and spatial smoothing of the normalized EPIs (FWHM = 6 mm).
3 Statistical analysis of the fMRI data was based on voxel-wise general linear models (GLMs) that
4 included two onset regressors, representing novel images (*novelty* regressor) and master images
5 (*master* regressor), six head motion regressors obtained from realignment and a constant
6 representing the implicit baseline. The novelty regressor was parametrically modulated with the
7 arcsine-transformed subsequent memory response, yielding a regressor reflecting encoding
8 success (Appendix, eq. 1). This model (“GLM_1t-a”, cf. Table 3 in ³⁸) had emerged as the
9 winning theoretical parametric GLM from Bayesian model selection between fMRI models in an
10 independent cohort of healthy young and older adults²⁸, as well as in the HC, SCD and AD-rel
11 groups from the DELCODE study³⁸.

12

13 **Single-value fMRI scores**

14 fMRI contrast maps for novelty processing (novel vs. master images) and subsequent memory
15 (parametric memory regressor) were calculated for each subject (Supplementary Methods). From
16 both contrasts, two single-value fMRI scores were computed: FADE²² and SAME²⁹. The FADE
17 score is calculated as the average t-value of an older participant on a specific contrast in all
18 voxels in which young participants show a positive effect on this contrast, subtracted from the
19 average t-value of the same contrast outside those voxels (Appendix, eq. 2). The SAME score is
20 calculated as the average of reduced activations of an older individual in all voxels in which
21 young adults show a positive effect, plus the average of reduced deactivations in all voxels with a
22 negative effect (Appendix, eq. 3).

23 In addition to the directionality, the SAME scores differ from the FADE scores by:

- 24 1. their (semi-)quantitative nature as they reflect voxel-wise differences between the subject’s
25 and reference sample’s parameter estimates rather than the average t-values inside vs. outside
26 a binarized activation mask,
- 27 2. explicitly considering deactivations, particularly in default mode network (DMN) regions (cf.
28 Fig. 1a in ²⁹), which may reflect early disturbances of memory network integrity in
29 individuals, particularly in individuals with SCD²⁴, and

1 3. accounting for the variance within the reference sample (Appendix, eq. 3).

2 In a previous study on the neuropsychological correlates of the single-value scores, we have
3 shown that, despite FADE and SAME being negatively correlated, there are relationships with
4 cognitive performance measures unique to either FADE or SAME scores³⁰.

5 For more information on the calculation and interpretation of the scores, see the original
6 descriptions (cf. Fig. 1 and Appendix A in ²⁹).

7

8 **Psychometric testing**

9 Memory performance in the fMRI task was measured as “A-prime”, the area under the curve in a
10 receiver-operating characteristic (ROC) analysis of the subsequent memory reports (cf. Appendix
11 B in ²⁹).

12 Participants completed a battery of neuropsychological tests. The Mini-Mental State
13 Examination (MMSE) score^{45,52,53} was a main criterion for the diagnosis of MCI and mild AD.
14 The preclinical Alzheimer cognitive composite score (PACC5) is derived as a composite measure
15 based on the following neuropsychological test scores:

- 16 1. the Total Recall score from the Free and Cued Selective Reminding Test (FCSRT)⁵⁴,
- 17 2. the Delayed Recall score on the Logical Memory IIa subtest from the Wechsler Memory
18 Scale (WMS)⁵⁵,
- 19 3. the Digit Symbol Substitution Test score from the Wechsler Adult Intelligence Scale–Revised
20 (WAIS-R)⁵⁶,
- 21 4. the MMSE total score, and
- 22 5. category fluency as a measure of semantic knowledge⁴⁷.

23 For each subject, the PACC5 was defined as the sum of all z-transformed values from each sub-
24 score⁵⁷.

25 The neuropsychological test (NPT) score represents the mean score of five factors derived from a
26 factor analysis conducted on a large variety of neuropsychological tests⁴⁶. These include
27 components of the PACC5 and several subscales from the FCSRT, the Trail-Making Test, Clock

1 Drawing Test, additional WMS subscales (Logical Memory 1 and 2), the Face Naming Test,
2 Symbol digit modalities test, Boston Naming Task, and Flanker Task.

3

4 **Fluid biomarkers**

5 Amyloid-beta and tau epitopes in CSF ($A\beta$ -42/40 ratio, total Tau, p-Tau181) were determined
6 using commercially available kits according to vendor specifications: V-PLEX $A\beta$ Peptide Panel
7 1 (6E10) Kit (K15200E) and V-PLEX Human Total Tau Kit (K151LAE) (Mesoscale Diagnostics
8 LLC, Rockville, USA), and Innostest Phospho-Tau (181P) (81581) (Fujirebio Germany GmbH,
9 Hannover, Germany). For more details on CSF biomarkers, see previous DELCODE
10 publications (e.g., ²³).

11 Genotypes of rs7412 and rs429358, the single nucleotide polymorphisms defining the ApoE ϵ 2,
12 ϵ 3, and ϵ 4 alleles, were identified using commercially available TaqMan® SNP Genotyping
13 Assay (ThermoFisher Scientific; for details, see previous DELCODE publications, e.g. ⁴⁴).

14

15 **Statistical analyses**

16 The goal of the present analyses was two-fold: First, we aimed to assess the robustness of FADE
17 and SAME scores against confounding variables (e.g., Table 2). Second, we aimed to assess
18 potential relationships of the scores with factors previously implicated in cognitive aging or
19 increased risk for developing AD dementia (e.g., Figure 5).

20 To investigate the robustness and stability of the scores, FADE and SAME scores were (i)
21 subjected to between-subject ANOVAs using site, gender and diagnostic group as factors, (ii)
22 analyzed with score-wise mixed ANOVAs using diagnosis and contrast as factors, and (iii)
23 computed based on different reference samples.

24 To investigate relationships between the scores and variables relevant for cognitive aging, FADE
25 and SAME scores were analyzed as a function of (i) baseline diagnosis, (ii) chronological age,
26 (iii) memory performance in the fMRI task, (iv) educational and employment years, (v)
27 demographic/lifestyle factors like BMI, (vi) neuropsychological test scores such as MMSE, NPT

1 and PACC5, (vii) fluid biomarkers (total-tau, p-Tau181, A β -42/40 ratio), and the categorical
2 variables (viii) amyloid positivity, (ix) ApoE genotype, and (x) educational status.

3 In total, these investigations resulted in ten statistical analyses (Table S1). All analyses, except
4 for the mixed ANOVAs, were conducted and are reported separately for each combination of
5 contrast and score (i.e., for all four types of scores: novelty-FADE, novelty-SAME, memory-
6 FADE, memory-SAME; e.g., Figure 2).

7

8 **Predictive analyses**

9 To assess the predictive utility of the single-value fMRI scores, we performed support vector
10 machine (SVM) classification analyses, using all four scores as features and grouping the entire
11 sample into several distinct subgroups, based on, for example, diagnostic group, ApoE genotype
12 or Amyloid status (Table S4).

13 In each classification analysis, SVMs were calibrated with regularization hyperparameter $C = 1$
14 and using $k = 10$ -fold cross-validation. To account for unequal sample sizes among participant
15 groups, we repeatedly drew subsamples with a constant number of observations per class.
16 Classification accuracy and 90% confidence interval as measures of predictive performance were
17 obtained as averages across all $S = 1000$ subsamples. All predictive analyses were implemented
18 using Machine Learning for MATLAB (<https://github.com/JoramSoch/ML4ML>).

19

20 **Results**

21 **Novelty- and memory-related fMRI responses across diagnostic** 22 **groups**

23 We first investigated the voxel-wise differences between participant groups with respect to
24 novelty and memory contrasts. To this end, we computed a second-level one-way ANOVA in
25 SPM with diagnostic group (HC, SCD, MCI, AD, AD-rel) as between-subjects factor, and
26 thresholded the statistical map for a parametric effect of diagnosis (Figure 1E), corrected for

1 family-wise error (FWE) at cluster level (cluster-defining threshold, CDT = 0.001, extent
2 threshold $k = 35$ (novelty) and $k = 32$ (memory); cf. ⁵⁸).

3 We found significant effects on both fMRI contrasts (Figure 1A/B), implicating brain regions
4 previously implicated in (visual) episodic memory formation (Figure S1), including MTL
5 regions like parahippocampal cortex (PHC) and hippocampus as well as the precuneus (PreCun)
6 and the temporo-parietal junction (TPJ).

7 Closer inspection of the activation patterns across participant groups (Figure 1C/D) revealed that
8 (i) some of these differences were based on reduced activations in AD risk states compared to
9 HC, especially in regions belonging to the human memory network (e.g. novelty: right PHC,
10 Figure 1C); and (ii) some of these effects resulted from reduced deactivations in AD disease
11 states compared to HC, especially in DMN regions (e.g. memory: left TPJ and PreCun, Figure
12 1D).

13

14 **FADE and SAME scores across the AD risk spectrum**

15 When comparing the single-value fMRI scores across participant groups, we observed three
16 tendencies. First, differences between healthy young and older participants replicate earlier
17 results²⁹, with significant effects of age group for all scores except for the FADE score from the
18 novelty contrast (Figure 2A). As the DELCODE study did not include young participants,
19 comparisons with young adults were conducted with the young participants from ²⁹ (for details,
20 see Supplementary Methods). Second, nominal differences largely mirrored the stages of the AD
21 risk spectrum, with increasing risk being associated with more atypical fMRI scores (SAME
22 scores: young > older \approx HC \approx AD-rel > SCD > MCI > AD; FADE scores: reverse order; Figure
23 2). Third, there were no significant differences between older subjects from ²⁹, healthy controls
24 from the DELCODE study, and AD relatives from the DELCODE study for any of the scores.
25 SCD and healthy participant groups (HC, AD-rel) only differed in the novelty-SAME score
26 (Figure 2B).

27 Memory-based scores did not significantly differ between the MCI and AD groups (FADE: $t_{93} =$
28 -0.67 , $p = 0.504$; SAME: $t_{93} = 1.34$, $p = 0.182$). They did, however, significantly differentiate
29 both groups from all other diagnostic groups (FADE: $t_{466} = -5.57$, $p < 0.001$.; SAME: $t_{466} = 5.46$,

1 $p < 0.001$; two-sample t-test for HC/SCD/AD-rel vs. MCI/AD; Figure 2C/D). Novelty-based
2 scores did not significantly differ between the MCI and SCD groups (FADE: $t_{271} = -1.90$, $p =$
3 0.058 ; SAME: $t_{271} = 1.66$, $p = 0.099$). They did, however significantly differentiate the MCI and
4 AD groups (FADE: $t_{93} = -3.52$, $p < 0.001$; SAME: $t_{93} = 3.05$, $p = 0.003$; Figure 2A/B).

5 When comparing novelty and memory contrasts, holding score type constant, we found
6 significant interactions of diagnosis and contrast for both scores (FADE: $F_{4,463} = 18.78$, $p <$
7 0.001 ; SAME: $F_{4,463} = 19.80$, $p < 0.001$; Supplementary Results and Table S3).

8

9 **Robustness and stability of FADE and SAME scores**

10 To control for potential confounding variables, we computed a three-way between-subjects
11 ANOVA to assess effects of (i) acquisition site (8 sites; cf. Table 1 in ³⁸), (ii) gender (male vs.
12 female), and (iii) diagnostic group (HC, SCD, MCI, AD, AD-rel). Because the factor site had
13 eight levels, we did not include interactions with site in this model. For detailed statistics, see
14 Table 2.

15 The main effect of site was significant for the novelty-FADE score, but not when correcting for
16 multiple comparisons (uncorrected $p = 0.023$). The main effect of gender was significant for all
17 four scores, reflecting higher FADE scores and lower SAME scores in men compared to women
18 (Figure S2), but not when correcting for multiple comparisons (uncorrected p -values in range
19 $0.016 < p < 0.043$). Main effects of diagnostic group remained significant for all scores when
20 controlling for site and gender. There were no interactions between gender and diagnostic group.

21 Importantly, in addition to their robustness to gender and acquisition site, the scores were also
22 stable when using a different, independent sample of young adults as reference (Supplementary
23 Methods, Results, Table S5, Figures S3 and S4).

24

25 **FADE and SAME scores correlate with indices of cognitive aging** 26 **and AD risk**

27 To identify associations of the scores with indices of cognitive aging beyond diagnostic group,
28 we computed partial correlations between the scores (novelty/memory x FADE/SAME) and

1 markers of cognitive functioning (e.g., memory performance) lifestyle or demographic factors
 2 (e.g., BMI, education), and neurochemical and genetic markers (e.g., A β -42/40 ratio). To account
 3 for diagnostic group (HC, SCD, MCI, AD, AD-rel), we computed the correlations between
 4 residual independent variables and residual fMRI scores after removing group-wise means from
 5 both, correcting for multiple comparisons.

6 These partial correlations revealed several patterns (Figure 3): FADE and SAME scores (i) show
 7 significant correlations with chronological age, mainly supported by the large SCD group
 8 (Supplementary Methods, Results, Figures S7 and S8), (ii) correlate significantly with memory
 9 performance in the fMRI task (A-prime; Section “Psychometric testing”), (iii) are not
 10 significantly correlated with lifestyle-driven factors such as educational (for details, see
 11 Supplementary Methods, Results, and Figure S6) and employment years as well as height,
 12 weight and BMI; (iv) show weakly significant correlations with MMSE and stronger significant
 13 correlations with NPT and PACC5 scores, and, finally, (v) there is weak evidence for an
 14 association with total tau and phospho-tau and robust evidence for an association with the A β
 15 42/40 ratio, but only for novelty-based scores.

17 **Effects of ApoE genotype in AD relatives**

18 Before assessing effects of ApoE genotype on fMRI scores, we investigated the distribution of
 19 ApoE genotypes within each diagnostic group. We computed chi-squared goodness-of-fit tests
 20 comparing the actual occurrences of genotypes to expected frequencies obtained from a
 21 comparable population⁶⁰.

22 Individuals with MCI or AD differed significantly from the population distribution with higher
 23 frequencies of ϵ 3/ ϵ 4 and ϵ 4/ ϵ 4 (Figure S5 and Table 3), compatible with the higher frequency of
 24 the ϵ 4 allele in AD.

25 A between-subjects ANOVA on the fMRI scores with diagnostic group (HC, SCD, MCI, AD,
 26 AD-rel) and ApoE genotype (ϵ 3 homozygotes vs. ϵ 4 carriers) as fixed factors, yielded a
 27 significant main effect of ApoE for all scores except the novelty-FADE score, but not when
 28 correcting for multiple comparisons (novelty-FADE: $F_{1,393} = 1.11$, $p = 0.293$; novelty-SAME:
 29 $F_{1,393} = 5.14$, $p = 0.024$; memory-FADE: $F_{1,393} = 6.54$, $p = 0.011$; memory-SAME: $F_{1,393} = 4.24$, p

1 = 0.040). When calculating post-hoc tests comparing the scores between ApoE ϵ 4 carriers and ϵ 3
 2 homozygotes in each diagnostic group, we found significant differences among the AD relatives
 3 (novelty-FADE: $t_{41} = -2.56$, $p = 0.014$; novelty-SAME: $t_{41} = 2.45$, $p = 0.019$; memory-FADE: t_{41}
 4 = -2.20 , $p = 0.034$; memory-SAME: $t_{41} = 1.48$, $p = 0.146$), but not in other groups (all $p > 0.058$;
 5 Figure 4). Thus, the increased genetic risk in AD relatives was also reflected by FADE and
 6 SAME scores.

7

8 **Effects of amyloid positivity in SCD and AD relatives**

9 Finally, we examined a potential association of the scores with amyloid positivity, defined by the
 10 CSF A β -42/40 ratio (value ≤ 0.08 considered as A+; according to ⁴⁸). Initial omnibus between-
 11 subjects ANOVAs with diagnostic group (HC, SCD, MCI, AD, AD-rel) and amyloid positivity
 12 (A+, A-) as fixed factors revealed a main effect of Amyloid for all scores, except for the
 13 memory-SAME score, after correcting for multiple comparisons (novelty-FADE: $F_{1,214} = 12.46$,
 14 $p < 0.001$; novelty-SAME: $F_{1,214} = 10.59$, $p = 0.001$; memory-FADE: $F_{1,214} = 7.13$, $p = 0.008$;
 15 memory-SAME: $F_{1,214} = 4.25$, $p = 0.040$). When calculating post-hoc t-tests comparing
 16 participants by Amyloid status within each diagnostic group, we found that these effects were
 17 driven by higher FADE scores and lower SAME scores in A+ participants across all diagnostic
 18 groups. These differences were significant in individuals with SCD (novelty-FADE: $t_{90} = 2.57$, p
 19 = 0.012 ; novelty-SAME: $t_{90} = -2.52$, $p = 0.013$; memory-SAME: $t_{90} = -2.05$, $p = 0.044$) and AD
 20 relatives (novelty-SAME: $t_{22} = -2.70$, $p = 0.013$), but not in the other groups (all other $p > 0.061$;
 21 Figure 5). Thus, our scores, especially the novelty-based scores, were indeed sensitive to amyloid
 22 positivity. However, given the small sample size in some subgroups (e.g., AD patients with A-,
 23 AD relatives with A+), those findings must be considered preliminary.

24

25 **Predictive utility of FADE and SAME scores**

26 When using all four scores for SVM classification, diagnostic group could be predicted with
 27 above-chance classification accuracy for several partitions, such as distinguishing all five groups
 28 (all participants; balanced accuracy, BA = 31.17%, confidence interval, CI = [23.54%, 39.12%])
 29 or the clinical groups (SCD, MCI, AD; BA = 49.27%, CI = [38.21%, 60.05%]), but also MCI and

1 AD from healthy controls (MCI vs. HC: BA = 68.94%, CI = [61.99%, 75.09%]; AD vs. HC: BA
2 = 78.03%, CI = [64.97%, 87.72%]).

3 In AD relatives, ApoE genotype could be predicted above chance (BA = 68.44%, CI = [51.37%,
4 82.39%]). The same was true for classification of Amyloid status in individuals with SCD, but
5 the confidence interval did not exclude chance level due to small sample sizes (BA = 55.65%, CI
6 = [43.88%, 66.52%]; for details, see Supplementary Table S4).

7

8 **Discussion**

9 We have explored the utility of single-value scores derived from memory-related fMRI contrast
10 maps as potential biomarkers across the AD risk spectrum (SCD, MCI, and AD, plus AD-rel).
11 We could replicate and extend earlier findings on the neurocognitive underpinnings of FADE and
12 SAME scores in healthy older adults^{29,30} and identified several characteristic associations of the
13 scores with neurobiological markers of AD risk. Among healthy older adults, we could largely
14 replicate our previous findings in voxel-wise fMRI data analysis (Figures 1C/D and S1). Single-
15 value scores also showed similar associations with neurocognitive measures and nuisance
16 variables (Figures 2, 3, 4, S6, and S7; Table 2; Supplementary Results).

17 **FADE and SAME scores across the AD risk continuum**

18 In line with our hypothesis, the fMRI scores show a continuous increase (FADE scores) or
19 decrease (SAME scores) across AD risk spectrum stages (Figure 2). In the SCD group, we
20 observed nominally higher FADE and lower SAME scores compared to HC, but the overall
21 pattern was largely preserved. Individuals with MCI, on the other hand, showed markedly higher
22 FADE scores and lower SAME scores for the memory contrast, whereas the novelty-based
23 scores showed only gradual differences to those from the SCD group (similar in magnitude as
24 between the HC and SCD groups). In the AD group, we additionally observed markedly altered
25 scores for the novelty contrast, which distinguished them from the MCI group. These findings
26 suggest that subsequent memory effects, and thus the FADE and SAME scores computed from
27 the memory contrast, might be more sensitive to small deviations from typical memory
28 processing, as they also reflect encoding success.

1 While these results are generally compatible with the notion that SCD and MCI can be
2 considered intermediate stages between healthy brain aging and manifest AD, they additionally
3 suggest qualitative differences with a substantial disruption of memory encoding-related brain
4 activity distinguishing MCI from SCD and an additional (i.e., more substantial) impairment of
5 novelty processing marking the transition from MCI to AD. Accelerated forgetting, resulting in
6 impaired long-term recall is impaired already early in the AD continuum. Specifically, recall
7 after prolonged retention intervals (e.g., several days) can be affected at pre-MCI stages, whereas
8 MCI is associated with impaired recall after intermediate retention intervals^{61,62}, such as the 70
9 min employed here, thereby allowing for a differentiation between individuals with MCI versus
10 SCD. On the other hand, the additional effect on the novelty-based scores in participants with
11 manifest AD may be best explained by a broader deficit present at the initial encoding stage
12 already^{61,62}. Within this framework, future studies should further explore the relationship
13 between FADE and SAME scores and retrieval after prolonged retention intervals in individuals
14 with SCD.

15

16 **Brain activity patterns underlying FADE and SAME scores**

17 When comparing voxel-wise fMRI contrasts across diagnostic groups, we found that differences
18 in scores could be attributed to both reduced temporo-parieto-occipital memory network
19 activations and reduced DMN deactivations (Figure 1). They thus mirror previously described
20 activation differences between healthy older adults and individuals with MCI or AD^{31-34,24}.
21 Qualitatively, these patterns are similar to memory-related fMRI activation differences between
22 healthy young and older adults^{25,29,51}. One interpretation of the observed pattern would therefore
23 be that progressive deterioration of memory-related brain activity across the AD risk spectrum
24 might reflect accelerated neurocognitive aging.

25 Notably, individuals with SCD exhibited largely preserved temporo-parietal memory network
26 activations during novelty processing and successful encoding, but reduced novelty-related
27 deactivations of DMN structures like the precuneus (Figure 1), replicating previous results based
28 on a different first-level GLM²⁴. This observation is compatible with earlier findings suggesting
29 that age-related reduced deactivations of DMN structures are associated with lower memory

1 performance²⁵ and with the notion that reduced inhibitory activity may constitute an early
2 mechanism of neurocognitive aging^{63,64}.

3 In the more severely affected diagnostic groups (i.e., MCI and AD), we additionally observed
4 reduced activations of the MTL and parieto-occipital memory network structures (Figures 1 and
5 S1). In the novelty contrast, these were primarily observed in AD patients, whereas both the MCI
6 and the AD group exhibited reduced temporo-parieto-occipital network activity in the memory
7 contrast, reflecting the pattern of FADE and SAME scores. Using Bayesian model selection of
8 first-level fMRI models, we found that in both groups, a memory-invariant model was favored
9 over even the most parsimonious subsequent memory models³⁸. Additionally, the AD group also
10 showed a substantially lower number of voxels favoring a novelty model over a purely
11 perceptual model not considering novelty. Therefore, a straightforward explanation for the higher
12 FADE and lower SAME scores in the MCI and AD groups may be that the memory contrasts and
13 – in the case of the AD group, also the novelty contrasts – underlying the scores might exhibit a
14 lower signal-to-noise ratio resulting from a suboptimal model fit in these diagnostic groups.

16 **FADE and SAME scores as indices of neurocognitive aging**

17 Across the cohort, FADE and SAME scores correlated with neuropsychological measures like
18 MMSE, NPT and PACC5, after controlling for diagnostic group (Figure 3). This pattern is in line
19 with previous observations that the scores reflect indices of neurocognitive age differences^{22,29,30}.
20 A previous evaluation of the FADE and SAME scores in healthy older adults has suggested that
21 all scores correlate with delayed episodic recall performance, and memory-based scores
22 additionally correlate with more global measures of cognition³⁰.

23 While we previously found no correlation between memory performance in the fMRI task and
24 the FADE score derived from the novelty contrast^{29,30}, this correlation was significant in the
25 present study, possibly due to a larger sample size. We could nevertheless replicate the
26 observation that memory performance in the fMRI task showed a stronger correlation with the
27 scores computed from the memory contrast as compared to the novelty contrast²⁹. Correlations
28 with independent neuropsychological indices (NPT global, PACC5 score) were similar in
29 magnitude across the four scores, albeit nominally stronger for the novelty-based scores,

1 tentatively suggesting a potentially higher prognostic value with respect to prediction of
2 cognitive functioning in individuals at risk for AD. That said, computing the scores from the
3 memory contrast may nevertheless be beneficial for differentiating individuals with SCD from
4 individuals with MCI (Section “FADE and SAME scores across the AD risk continuum“).
5 Furthermore, particularly the memory-SAME score may be suitable for the prediction of
6 individual differences of cognitive performance in healthy older adults^{39,30,65}.

7

8 **Single-value scores, amyloid status, and genetic risk**

9 While the differential patterns of FADE and SAME scores observed here (Figure 2) allow for a
10 separation of individuals with SCD, MCI, and AD, their diagnostic value for differentiating
11 individuals with SCD from healthy controls is less clear. Likewise, scores in healthy relatives of
12 patients with AD were essentially indistinguishable from those of the HC group. However, these
13 groups exhibited specific associations between the scores and markers of Alzheimer’s pathology
14 ($A\beta$ -42/40 ratio) and genetic risk (ApoE ϵ 4 allele carriage).

15 Among all participants with available CSF samples, novelty-based FADE and SAME scores
16 differed as a function of $A\beta$ -42/40 ratio (Figure 3). When testing for effects of amyloid positivity
17 separately in each group, the effect was only significant in the SCD (novelty-FADE and SAME
18 scores) and AD-rel groups (novelty-SAME score; Figure 5). This observation opens a potential
19 perspective for the scores as diagnostic or prognostic markers of AD risk in SCD. Individuals
20 with SCD typically report memory problems, despite objectively normal or only mildly impaired
21 neuropsychological test performance^{12,13}, and minor neuropsychological deficits in SCD have
22 been linked to reduced $A\beta$ -42/40 ratios and increased p-tau181 levels in CSF⁴⁶. Amyloid
23 positivity in SCD has recently been associated with subsequent clinical progression to MCI⁴⁸ and
24 with lower hippocampal volumes⁶⁶. Therefore, FADE and SAME scores – and perhaps
25 particularly the novelty-SAME score – may constitute novel non-invasive predictors for the
26 progression to MCI in individuals with SCD.

27 A similar pattern was found in AD relatives whose FADE and SAME scores did, on average not
28 differ from those of HC. Unlike previous studies of neuropsychological performance in healthy
29 relatives of patients with AD (for a review, see ⁶⁷), we additionally found no performance

1 difference between healthy relatives and control participants (see Fig. 1 in ³⁸). However, unlike
2 HC and similar to individuals with SCD, healthy relatives exhibited a significant effect of
3 amyloid positivity on the novelty-SAME score (Figure 5). This is in line with the observation
4 that, in the same cohort, amyloid positivity has been associated with higher subjective cognitive
5 decline in the relatives⁴⁶. Additionally, AD relatives were the only group in which we found an
6 association of the scores with ApoE genotype (Figure 4). This suggests that indices of subtle
7 cognitive impairment in relatives of patients with AD (i.e., higher FADE and lower SAME
8 scores) reflect, at least in part, genetic risk and is compatible with previously reported synergistic
9 effects of ApoE ϵ 4 carriage and AD family history on brain amyloid deposition⁶⁸. Note that
10 relatives carrying the ApoE ϵ 4 allele have previously been shown to display lower performance
11 in cognitive tests⁶⁷. While ApoE ϵ 4 carriage, and particularly ϵ 4 homozygosity, is the strongest
12 risk factor for sporadic (late-onset) AD, future studies should further assess the role of polygenic
13 risk on fMRI-based scores and their trajectories in relatives of AD patients.

14

15 **Limitations and directions for future research**

16 One limitation of our study is that the BOLD signal underlying the fMRI activation patterns and
17 thus FADE and SAME scores is an indirect measure of neural activity and profoundly influenced
18 by vascular and metabolic factors. While dynamic cerebral autoregulation, a key mechanism of
19 regulating cerebral blood flow, is largely preserved, at least macroscopically, in MCI and AD⁶⁹,
20 small-vessel disease like Amyloid angiopathy is commonly associated with AD and can impair
21 neurovascular coupling⁷⁰, which may in turn contribute to a blunted BOLD signal, particularly in
22 MCI or AD. On the other hand, even if the pattern of FADE and SAME scores in the MCI and
23 AD groups can, at least partly, be attributed to vascular or metabolic differences, this should not
24 necessarily affect their potential diagnostic value. However, caution is warranted with respect to
25 the interpretation of underlying neural mechanisms.

26 Another limitation concerns the composition of the sample, as participant groups significantly
27 differed regarding age range, gender ratio, acquisition site, ApoE genotype, CSF biomarkers and
28 neuropsychological measures (Table 1). While some of these imbalances directly result from the
29 study design, reflecting expected differences in neuropsychological scores and fluid biomarkers,
30 other variables like age or gender constitute potential confounds. Here, we aimed to statistically

1 control for such factors while maximizing the sample size to increase statistical power. It must be
2 noted, though, that, for example, gender effects may be worthwhile to investigate in more
3 detail^{71,72}. On the other hand, the sample was ethnically and socio-demographically rather
4 homogenous, most likely owing to our recruiting strategy via memory clinics and newspaper
5 advertisements. Further studies should assess the generalizability of our findings to individuals
6 from different ethnic and cultural backgrounds^{73,74}.

7 Furthermore, while SVM classifications allowed us to explore the predictive utility of the scores
8 to some extent, a longitudinal study is needed to assess whether the scores actually bear a
9 prognostic value in individuals at risk for AD.

10 Another limitation is that the FADE and SAME scores are inherently linked to a reference
11 cohort. We have previously shown their robustness with respect to different reference samples of
12 young adults, although smaller samples were associated with steeper slopes and non-zero
13 intercepts²⁹. A similar relationship was found when using a sample of healthy older adults of
14 similar size as reference (Supplementary Methods, Results, and Figure S4). Importantly, the
15 relationship between the scores based on different reference samples was essentially linear, thus
16 affecting their absolute value, but not their distribution in the study population (see
17 Supplementary Discussion). Ultimately, the strongest evidence for the robustness of the scores
18 would, in our view, be a proof of test-retest reliability, possibly moderated by cognitive decline
19 (i.e., scores of subsequent decliners being less stable over time than those of individuals with
20 longitudinally preserved cognitive function) and/or Amyloid status. This will be addressed in
21 future work.

22

23 **Conclusions**

24 We have demonstrated a use case for reductionist single-value scores, computed from whole-
25 brain fMRI contrast maps, across the trajectories of the AD risk spectrum in a cross-sectional
26 design. FADE and SAME scores vary as a function of disease status group (i.e., MCI vs. AD),
27 whereas in individuals with moderately elevated risk (i.e., SCD and AD-rel), the scores
28 distinguish individuals with and without additional risk factors (i.e., A β 42/40 ratio, ApoE
29 genotype). Our results demonstrate the potential utility of FADE and SAME scores as fMRI-

1 based biomarkers for neurocognitive functioning in individuals at risk for AD, but longitudinal
2 studies are needed to evaluate a potential prognostic use.

3

4 **Data availability**

5 Data from the DELCODE study are available via individual data sharing agreements with the
6 DELCODE study board (for more information, see
7 <https://www.dzne.de/en/research/studies/clinical-studies/delcode/>). The code used for computing
8 the FADE and SAME scores has been published previously²⁹ and is available via GitHub
9 (https://github.com/JoramSoch/DELCODE_SAME).

10

11 **Acknowledgements**

12 We would like to thank all the participants in the DELCODE study and all the technical, medical
13 and psychological staff for making this study possible.

14 Special thanks go to the Max Delbrück Center for Molecular Medicine (MDC) within the
15 Helmholtz Association, the Center for Cognitive Neuroscience Berlin (CCNB) at the Free
16 University of Berlin, the Bernstein Center for Computational Neuroscience (BCCN) Berlin, the
17 MR research core facility of the University Medical Center Göttingen (UMG) and the MR
18 research center of the University Hospital Tübingen (UKT).

19

20 **Funding**

21 This work was supported by the German Center for Neurodegenerative Diseases (Deutsches
22 Zentrum für Neurodegenerative Erkrankungen, DZNE; reference number BN012). The authors
23 further received support from the Deutsche Forschungsgemeinschaft (CRC 1436, A05 and Z03)
24 and from the European Union and the State of Saxony-Anhalt (Research Alliance “Autonomy in
25 Old Age”).

26

1 **Competing interests**

2 F. Jessen has received consulting fees from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal,
3 Janssen, and Lundbeck. E. Düzel is co-founder of neotiv GmbH. The remaining authors report
4 no competing interests.

6 **Supplementary material**

7 Supplementary material is available at *Brain* online.

9 **Appendix 1**

11 **Parametric modulator reflecting encoding success**

12 In the voxel-wise GLM for first-level fMRI analysis, values for the parametric modulator (PM)
13 regressor were given by

$$14 \quad \text{PM} = \arcsin\left(\frac{x-3}{2}\right) \cdot \frac{2}{\pi} \quad (1)$$

15 where $x \in \{1, 2, 3, 4, 5\}$ is the later subsequent memory report, such that the transformation
16 ensures that $-1 \leq \text{PM} \leq +1$.

17 The use of the arcsine function in the transformation causes definitely remembered or forgotten
18 items (1, 5) to be weighted stronger relative to probably remembered or forgotten items (2, 4)
19 than when using a linear mapping.

21 **Calculation of single-value fMRI scores**

22 Let J_- and J_+ be the sets of voxels showing a negative effect or a positive effect, respectively, on
23 a particular contrast in young subjects at an *a priori* defined significance level ($p < 0.05$, FWE-

1 corrected, extent threshold $k = 10$), and let t_{ij} be the t-value of the i -th older subject in the j -th
 2 voxel on the same contrast. Then, the FADE score of this subject is given by

$$3 \quad \text{FADE}_i = \frac{1}{v} \sum_{j \in J_+} t_{ij} - \frac{1}{v_+} \sum_{j \in J_+} t_{ij}$$

4 where v_+ and v is the number of voxels inside and outside J_+ , respectively.

5 Alternatively, let $\hat{\beta}_j$ be the average estimate on a particular contrast in young subjects, let $\hat{\sigma}_j$ be
 6 the standard deviation of young subjects on this contrast at the j -th voxel and let $\hat{\gamma}_{ij}$ be the
 7 contrast estimate of the i -th older subject at the j -th voxel. Then, the SAME score of this subject
 8 is the sum of averaged reduced activations in J_+ and averaged reduced deactivations in J_-

$$9 \quad \text{SAME}_i = \frac{1}{v_+} \sum_{j \in J_+} \frac{\hat{\gamma}_{ij} - \hat{\beta}_j}{\hat{\sigma}_j} + \frac{1}{v_-} \sum_{j \in J_-} \frac{\hat{\beta}_j - \hat{\gamma}_{ij}}{\hat{\sigma}_j} \quad (3)$$

10 where v_+ and v_- are the numbers of voxels in J_+ and J_- , respectively.

11

12 References

- 13 1. Anthony M, Lin F. A Systematic Review for Functional Neuroimaging Studies of Cognitive
 14 Reserve Across the Cognitive Aging Spectrum. *Archives of Clinical Neuropsychology*.
 15 2018;33(8):937-948. doi:10.1093/arclin/acx125
- 16 2. Cabeza R, Albert M, Belleville S, et al. Maintenance, reserve and compensation: the
 17 cognitive neuroscience of healthy ageing. *Nature Reviews Neuroscience*. 2018;19(11):701-
 18 710. doi:10.1038/s41583-018-0068-2
- 19 3. Li Q, Marcu DC, Palazzo O, et al. High neural activity accelerates the decline of cognitive
 20 plasticity with age in *Caenorhabditis elegans*. *eLife*. 2020;9:e59711. doi:10.7554/eLife.59711
- 21 4. Tulving E. Memory and consciousness. *Canadian Psychology / Psychologie canadienne*.
 22 1985;26(1):1-12. doi:10.1037/h0080017
- 23 5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of
 24 Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's

- 1 Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's*
2 *& Dementia*. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003
- 3 6. Gallagher M, Koh MT. Episodic memory on the path to Alzheimer's disease. *Current*
4 *Opinion in Neurobiology*. 2011;21(6):929-934. doi:10.1016/j.conb.2011.10.021
- 5 7. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care.
6 *The Lancet*. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6
- 7 8. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care:
8 2020 report of the Lancet Commission. *The Lancet*. 2020;396(10248):413-446.
9 doi:10.1016/S0140-6736(20)30367-6
- 10 9. Nyberg L, Pudas S. Successful Memory Aging. *Annu Rev Psychol*. 2019;70(1):219-243.
11 doi:10.1146/annurev-psych-010418-103052
- 12 10. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild Cognitive
13 Impairment: Clinical Characterization and Outcome. *Arch Neurol*. 1999;56(3):303.
14 doi:10.1001/archneur.56.3.303
- 15 11. Grundman M. Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease
16 and Normal Aging for Clinical Trials. *Arch Neurol*. 2004;61(1):59.
17 doi:10.1001/archneur.61.1.59
- 18 12. Jessen F, Amariglio RE, Boxtel M, et al. A conceptual framework for research on subjective
19 cognitive decline in preclinical Alzheimer's disease. *Alzheimer's & Dementia*.
20 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001
- 21 13. Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive
22 decline. *The Lancet Neurology*. 2020;19(3):271-278. doi:10.1016/S1474-4422(19)30368-0
- 23 14. Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of
24 Alzheimer's disease based on biomarkers. *The Lancet Neurology*. 2017;16(8):661-676.
25 doi:10.1016/S1474-4422(17)30159-X
- 26 15. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in
27 Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *The Lancet*
28 *Neurology*. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0

- 1 16. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. *Nature*.
2 2018;561(7721):45-56. doi:10.1038/s41586-018-0457-8
- 3 17. Tsapanou A, Habeck C, Gazes Y, et al. Brain biomarkers and cognition across adulthood.
4 *Hum Brain Mapp*. Published online May 21, 2019:hbm.24634. doi:10.1002/hbm.24634
- 5 18. Diaz-de-Grenu LZ, Acosta-Cabronero J, Pereira JMS, Pengas G, Williams GB, Nestor PJ.
6 MRI detection of tissue pathology beyond atrophy in Alzheimer's disease: Introducing T2-
7 VBM. *NeuroImage*. 2011;56(4):1946-1953. doi:10.1016/j.neuroimage.2011.03.082
- 8 19. Minkova L, Habich A, Peter J, Kaller CP, Eickhoff SB, Klöppel S. Gray matter asymmetries
9 in aging and neurodegeneration: A review and meta-analysis: VBM-ALE Analysis of GM
10 Asymmetries. *Hum Brain Mapp*. 2017;38(12):5890-5904. doi:10.1002/hbm.23772
- 11 20. Dounavi ME, Mak E, Wells K, et al. Volumetric alterations in the hippocampal subfields of
12 subjects at increased risk of dementia. *Neurobiology of Aging*. 2020;91:36-44.
13 doi:10.1016/j.neurobiolaging.2020.03.006
- 14 21. Arvanitakis Z, Fleischman DA, Arfanakis K, Leurgans SE, Barnes LL, Bennett DA.
15 Association of white matter hyperintensities and gray matter volume with cognition in older
16 individuals without cognitive impairment. *Brain Struct Funct*. 2016;221(4):2135-2146.
17 doi:10.1007/s00429-015-1034-7
- 18 22. Düzel E, Schütze H, Yonelinas AP, Heinze HJ. Functional phenotyping of successful aging in
19 long-term memory: Preserved performance in the absence of neural compensation.
20 *Hippocampus*. 2011;21:803-814. doi:10.1002/hipo.20834
- 21 23. Düzel E, Ziegler G, Berron D, et al. Amyloid pathology but not APOE ϵ 4 status is permissive
22 for tau-related hippocampal dysfunction. *Brain*. 2022;145(4):1473-1485.
23 doi:10.1093/brain/awab405
- 24 24. Billette OV, Ziegler G, Aruci M, et al. Novelty-Related fMRI Responses of Precuneus and
25 Medial Temporal Regions in Individuals at Risk for Alzheimer Disease. *Neurology*.
26 2022;99(8):e775-e788. doi:10.1212/WNL.0000000000200667
- 27 25. Maillet D, Rajah MN. Age-related differences in brain activity in the subsequent memory
28 paradigm: A meta-analysis. *Neuroscience & Biobehavioral Reviews*. 2014;45:246-257.
29 doi:10.1016/j.neubiorev.2014.06.006

- 1 26. Kim H. Neural activity that predicts subsequent memory and forgetting: A meta-analysis of
2 74 fMRI studies. *NeuroImage*. 2011;54(3):2446-2461.
3 doi:10.1016/j.neuroimage.2010.09.045
- 4 27. Henson RNA, Shallice T, Gorno-Tempini ML, Dolan RJ. Face Repetition Effects in Implicit
5 and Explicit Memory Tests as Measured by fMRI. *Cerebral Cortex*. 2002;12(2):178-186.
6 doi:10.1093/cercor/12.2.178
- 7 28. Soch J, Richter A, Schütze H, et al. Bayesian model selection favors parametric over
8 categorical fMRI subsequent memory models in young and older adults. *NeuroImage*.
9 2021;230:117820. doi:10.1016/j.neuroimage.2021.117820
- 10 29. Soch J, Richter A, Schütze H, et al. A comprehensive score reflecting memory-related fMRI
11 activations and deactivations as potential biomarker for neurocognitive aging. *Hum Brain*
12 *Mapp*. 2021;42(14):4478-4496. doi:10.1002/hbm.25559
- 13 30. Richter A, Soch J, Kizilirmak JM, et al. Single-value scores of memory-related brain activity
14 reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging.
15 *Human Brain Mapping*. Published online March 27, 2023:hbm.26281.
16 doi:10.1002/hbm.26281
- 17 31. Browndyke JN, Giovanello K, Petrella J, et al. Phenotypic regional functional imaging
18 patterns during memory encoding in mild cognitive impairment and Alzheimer's disease.
19 *Alzheimer's & Dementia*. 2013;9(3):284-294. doi:10.1016/j.jalz.2011.12.006
- 20 32. Nellessen N, Rottschy C, Eickhoff SB, et al. Specific and disease stage-dependent episodic
21 memory-related brain activation patterns in Alzheimer's disease: a coordinate-based meta-
22 analysis. *Brain Struct Funct*. 2015;220(3):1555-1571. doi:10.1007/s00429-014-0744-6
- 23 33. Terry DP, Sabatinelli D, Puente AN, Lazar NA, Miller LS. A Meta-Analysis of fMRI
24 Activation Differences during Episodic Memory in Alzheimer's Disease and Mild Cognitive
25 Impairment: fMRI Activation Differences during Episodic Memory in AD/MCI. *J*
26 *Neuroimaging*. 2015;25(6):849-860. doi:10.1111/jon.12266
- 27 34. Wang P, Li J, Li HJ, Huo L, Li R. Mild Cognitive Impairment Is Not "Mild" at All in Altered
28 Activation of Episodic Memory Brain Networks: Evidence from ALE Meta-Analysis. *Front*
29 *Aging Neurosci*. 2016;8. doi:10.3389/fnagi.2016.00260

- 1 35. Gould RL, Brown RG, Owen AM, Bullmore ET, Williams SCR, Howard RJ. Functional
2 Neuroanatomy of Successful Paired Associate Learning in Alzheimer's Disease. *AJP*.
3 2005;162(11):2049-2060. doi:10.1176/appi.ajp.162.11.2049
- 4 36. Kircher TT, Weis S, Freymann K, et al. Hippocampal activation in patients with mild
5 cognitive impairment is necessary for successful memory encoding. *Journal of Neurology,*
6 *Neurosurgery & Psychiatry*. 2007;78(8):812-818. doi:10.1136/jnnp.2006.104877
- 7 37. Trivedi MA, Murphy CM, Goetz C, et al. fMRI Activation Changes during Successful
8 Episodic Memory Encoding and Recognition in Amnesic Mild Cognitive Impairment
9 Relative to Cognitively Healthy Older Adults. *Dement Geriatr Cogn Disord*. 2008;26(2):123-
10 137. doi:10.1159/000148190
- 11 38. Soch J, Richter A, Kizilirmak JM, et al. Diminished Utility of FMRI Subsequent Memory
12 Models with Increasing Severity across the Alzheimer's Disease Risk Spectrum. *medRxiv*
13 *Neurology*; 2023. doi:10.1101/2023.09.11.23295362
- 14 39. Soch J, Richter A, Kizilirmak JM, et al. Structural and Functional MRI Data Differentially
15 Predict Chronological Age and Behavioral Memory Performance. *eNeuro*.
16 2022;9(6):ENEURO.0212-22.2022. doi:10.1523/ENEURO.0212-22.2022
- 17 40. van der Flier WM, Pijnenburg YAL, Schoonenboom SNM, Dik MG, Blankenstein MA,
18 Scheltens P. Distribution of APOE Genotypes in a Memory Clinic Cohort. *Dement Geriatr*
19 *Cogn Disord*. 2008;25(5):433-438. doi:10.1159/000124750
- 20 41. Janssen O, Jansen WJ, Vos SJB, et al. Characteristics of subjective cognitive decline
21 associated with amyloid positivity. *Alzheimer's & Dementia*. 2022;18(10):1832-1845.
22 doi:10.1002/alz.12512
- 23 42. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of Amyloid and Tau With
24 Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. *JAMA Neurol*.
25 2019;76(8):915. doi:10.1001/jamaneurol.2019.1424
- 26 43. Lewczuk P, Riederer P, O'Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for
27 neurodegenerative dementias: An update of the Consensus of the Task Force on Biological
28 Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *The*

- 1 World Journal of Biological Psychiatry. 2018;19(4):244-328.
2 doi:10.1080/15622975.2017.1375556
- 3 44. Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter
4 observational study on predementia Alzheimer's disease (DELCODE). *Alzheimer's Research
5 and Therapy*. 2018;10(1):1-10. doi:10.1186/s13195-017-0314-2
- 6 45. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading
7 the cognitive state of patients for the clinician. *Journal of Psychiatric Research*.
8 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6
- 9 46. Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients
10 with subjective cognitive decline. *Neurology*. 2020;95(9):e1134-e1143.
11 doi:10.1212/WNL.0000000000010142
- 12 47. Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical
13 Alzheimer's cognitive composite with semantic processing: The PACC5. *Alzheimer's &
14 Dementia: Translational Research & Clinical Interventions*. 2017;3(4):668-677.
15 doi:10.1016/j.trci.2017.10.004
- 16 48. Jessen F, Wolfsgruber S, Kleineidam L, et al. Subjective cognitive decline and stage 2 of
17 Alzheimer disease in patients from memory centers. *Alzheimer's & Dementia*. Published
18 online April 22, 2022;alz.12674. doi:10.1002/alz.12674
- 19 49. Düzel E, Berron D, Schütze H, et al. CSF total tau levels are associated with hippocampal
20 novelty irrespective of hippocampal volume. *Alzheimer's & Dementia: Diagnosis,
21 Assessment & Disease Monitoring*. 2018;10(1):782-790. doi:10.1016/j.dadm.2018.10.003
- 22 50. Bainbridge WA, Berron D, Schütze H, et al. Memorability of photographs in subjective
23 cognitive decline and mild cognitive impairment: Implications for cognitive assessment.
24 *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2019;11:610-
25 618. doi:10.1016/j.dadm.2019.07.005
- 26 51. Kizilirmak JM, Soch J, Schütze H, et al. The relationship between resting-state amplitude
27 fluctuations and memory-related deactivations of the default mode network in young and
28 older adults. *Human Brain Mapping*. 2023;44(9):3586-3609. doi:10.1002/hbm.26299

- 1 52. Beyermann S, Trippe RH, Bähr AA, Püllen R. Mini-Mental-Status-Test im stationären
2 geriatrischen Bereich: Eine Evaluation der diagnostischen Qualität. *Z Gerontol Geriat.*
3 2013;46(8):740-747. doi:10.1007/s00391-013-0488-6
- 4 53. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE)
5 for the detection of dementia in clinically unevaluated people aged 65 and over in community
6 and primary care populations. Cochrane Dementia and Cognitive Improvement Group, ed.
7 Cochrane Database of Systematic Reviews. Published online January 13, 2016.
8 doi:10.1002/14651858.CD011145.pub2
- 9 54. Grober E, Merling A, Heimlich T, Lipton RB. Free and cued selective reminding and
10 selective reminding in the elderly. *Journal of Clinical and Experimental Neuropsychology.*
11 1997;19(5):643-654. doi:10.1080/01688639708403750
- 12 55. Elwood RW. The Wechsler Memory Scale? Revised: Psychometric characteristics and clinical
13 application. *Neuropsychol Rev.* 1991;2(2):179-201. doi:10.1007/BF01109053
- 14 56. Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. Wechsler
15 Memory Scale – Revised Edition, German Edition. Manual. Huber; 2000.
16 <https://www.testothek.uni-konstanz.de/node/1697>
- 17 57. Donohue MC, Sperling RA, Salmon DP, et al. The Preclinical Alzheimer Cognitive
18 Composite: Measuring Amyloid-Related Decline. *JAMA Neurol.* 2014;71(8):961.
19 doi:10.1001/jamaneurol.2014.803
- 20 58. Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent
21 have inflated false-positive rates. *Proceedings of the National Academy of Sciences.*
22 2016;113(28):7900-7905. doi:10.1073/pnas.1602413113
- 23 59. Assmann A, Richter A, Schütze H, et al. Neurocan genome-wide psychiatric risk variant
24 affects explicit memory performance and hippocampal function in healthy humans. *European*
25 *Journal of Neuroscience.* 2020;(February):ejn.14872. doi:10.1111/ejn.14872
- 26 60. Li X, Hildebrandt A, Sommer W, et al. Cognitive Performance in Young APOE ε4 Carriers: A
27 Latent Variable Approach for Assessing the Genotype–Phenotype Relationship. *Behav Genet.*
28 2019;49(5):455-468. doi:10.1007/s10519-019-09961-y

- 1 61. Ally BA, Hussey EP, Ko PC, Molitor RJ. Pattern separation and pattern completion in
2 Alzheimer's disease: Evidence of rapid forgetting in amnesic mild cognitive impairment:
3 Pattern Separation in AMCI and AD. *Hippocampus*. 2013;23(12):1246-1258.
4 doi:10.1002/hipo.22162
- 5 62. Weston PSJ, Nicholas JM, Henley SMD, et al. Accelerated long-term forgetting in
6 presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. *The*
7 *Lancet Neurology*. 2018;17(2):123-132. doi:10.1016/S1474-4422(17)30434-9
- 8 63. Sambataro F, Murty VP, Callicott JH, et al. Age-related alterations in default mode network:
9 Impact on working memory performance. *Neurobiology of Aging*. 2010;31(5):839-852.
10 doi:10.1016/j.neurobiolaging.2008.05.022
- 11 64. Schott BH, Soch J, Kizilirmak JM, et al. Inhibitory temporo-parietal effective connectivity is
12 associated with explicit memory performance in older adults. *iScience*. 2023;26(10):107765.
13 doi:10.1016/j.isci.2023.107765
- 14 65. Stolz C, Bulla A, Soch J, Schott BH, Richter A. Openness to Experience Is Associated with
15 Neural and Performance Measures of Memory in Older Adults. *Neuroscience*; 2022.
16 doi:10.1101/2022.10.30.514257
- 17 66. Yildirim Z, Delen F, Berron D, et al. Brain reserve contributes to distinguishing preclinical
18 Alzheimer's stages 1 and 2. *Alz Res Therapy*. 2023;15(1):43. doi:10.1186/s13195-023-
19 01187-9
- 20 67. Ramos AA, Galiano-Castillo N, Machado L. Cognitive Functioning of Unaffected First-
21 degree Relatives of Individuals With Late-onset Alzheimer's Disease: A Systematic
22 Literature Review and Meta-analysis. *Neuropsychol Rev*. Published online September 3,
23 2022. doi:10.1007/s11065-022-09555-2
- 24 68. for the KBASE research group, Yi D, Lee Y, et al. Synergistic interaction between APOE and
25 family history of Alzheimer's disease on cerebral amyloid deposition and glucose
26 metabolism. *Alz Res Therapy*. 2018;10(1):84. doi:10.1186/s13195-018-0411-x
- 27 69. Heutz R, Claassen J, Feiner S, et al. Dynamic cerebral autoregulation in Alzheimer's disease
28 and mild cognitive impairment: A systematic review. *J Cereb Blood Flow Metab*. Published
29 online May 1, 2023:0271678X2311734. doi:10.1177/0271678X231173449

- 1 70. Eisenmenger LB, Peret A, Famakin BM, et al. Vascular contributions to Alzheimer's disease.
2 Translational Research. 2023;254:41-53. doi:10.1016/j.trsl.2022.12.003
- 3 71. Berezuk C, Khan M, Callahan BL, et al. Sex differences in risk factors that predict
4 progression from mild cognitive impairment to Alzheimer's dementia. J Int Neuropsychol
5 Soc. 2023;29(4):360-368. doi:10.1017/S1355617722000297
- 6 72. Nicoletti A, Baschi R, Cicero CE, et al. Sex and gender differences in Alzheimer's disease,
7 Parkinson's disease, and Amyotrophic Lateral Sclerosis: A narrative review. Mechanisms of
8 Ageing and Development. 2023;212:111821. doi:10.1016/j.mad.2023.111821
- 9 73. Dotson VM, Duarte A. The importance of diversity in cognitive neuroscience. Ann NY Acad
10 Sci. 2020;1464(1):181-191. doi:10.1111/nyas.14268
- 11 74. Jiang X, Hu X, Daamen M, et al. Altered limbic functional connectivity in individuals with
12 subjective cognitive decline: Converging and diverging findings across Chinese and German
13 cohorts. Alzheimer's & Dementia. Published online April 18, 2023:alz.13068.
14 doi:10.1002/alz.13068

16 **Figure legends**

17 **Figure 1 Diagnosis-related activation differences in the human memory network.** Encoding-
18 related fMRI activity was compared across five diagnosis groups (HC, SCD, MCI, AD, AD-rel).
19 Brain sections show significant effects of disease severity for (A) the novelty contrast (novel vs.
20 master images) and (B) the memory contrast (subsequent memory regressor), obtained using (E)
21 a parametric F-contrast ($c = [+3, +1, -1, -3, 0]$) testing for a linear decrease or increase with
22 disease progression (excluding AD relatives, because they cannot be meaningfully included into
23 the rank order of AD risk stages). Voxel colors indicate average differences between healthy
24 controls and Alzheimer's patients, resulting from either higher activity in disease ($AD > HC$, red)
25 or higher activity in health ($HC > AD$, blue). Bar plots show group-level contrast estimates and
26 90% confidence intervals for (C) the novelty contrast (novel vs. master images) and (D) the
27 memory contrast (subsequent memory regressor), extracted from the local maxima in A and B.
28 Statistics inside the panels correspond to (E) an F-contrast testing for a parametric increase or
29 decrease with disease severity (F/p-values; all F-values are $F_{1,463}$ statistics) and t-contrasts testing

1 each group against healthy controls (significance markers). Abbreviations: HC = healthy
 2 controls, SCD = subjective cognitive decline, MCI = mild cognitive impairment, AD =
 3 Alzheimer's disease, AD-rel = AD relatives. Significance: * $p < 0.05$, Bonferroni-corrected for
 4 ** number of tests per region (4) or *** number of tests and number of regions (4 x 2).

5
 6 **Figure 2 FADE and SAME scores as a function of fMRI contrast, score type and diagnostic**
 7 **group.** Single-value fMRI scores are shown as violin and sina plots for (A) the FADE score and
 8 (B) the SAME score computed from the novelty contrast as well as (C) the FADE score and (D)
 9 the SAME score computed from the memory contrast. Scores were calculated for young (green)
 10 and older (light blue) subjects from the original study as well as HCs (dark blue), individuals
 11 with SCD (yellow), MCI patients (orange), AD patients (red) and AD relatives (violet) from the
 12 DELCODE study. Sample sizes are given in the upper-left panel. Horizontal bars correspond to
 13 group-wise means. Statistics inside the panels correspond to a two-sample t-test between young
 14 and older adults (t/p-value; 215 degrees of freedom, DOF), a one-way ANOVA across
 15 DELCODE diagnostic groups (F/p-value; 4 numerator and 463 denominator DOFs) and two-
 16 sample t-tests of each group against DELCODE healthy controls (significance markers).
 17 Abbreviations: FADE = functional activity deviation during encoding, SAME = similarities of
 18 activations during memory encoding, HC = healthy controls, SCD = subjective cognitive decline,
 19 MCI = mild cognitive impairment, AD = Alzheimer's disease, AD-rel = AD relatives.
 20 Significance: * $p < 0.05$, Bonferroni-corrected for ** number of tests per score (6) or ***
 21 number of tests and number of scores (6 x 4). This figure extends results reported earlier (see
 22 Fig. 3 in ²⁹).

23
 24 **Figure 3 Partial correlations of FADE and SAME scores with other indices of cognitive**
 25 **aging.** Positive (red) and negative (blue) partial correlations of single-value fMRI scores (y-axis)
 26 with selected independent variables (x-axis), accounting for participant group membership.
 27 Abbreviations: FADE = functional activity deviation during encoding, SAME = similarities of
 28 activations during memory encoding, A-prime = memory performance, BMI = body-mass index,
 29 MMSE = mini-mental state examination^{45,44}, NPT = neuropsychological testing⁴⁶, PACC5 =
 30 preclinical Alzheimer's cognitive composite including the category fluency measure⁴⁷.

1 Significance: * $p < 0.05$, Bonferroni-corrected for ** number of independent variables (16) or
2 *** number of variables and number of scores (16 x 4).

3

4 **Figure 4 FADE and SAME scores by diagnostic group and ApoE genotype.** Single-value
5 fMRI scores are shown for (A) the FADE score and (B) the SAME score computed from the
6 novelty contrast as well as (C) the FADE score and (D) the SAME score computed from the
7 memory contrast. The layout follows that of Figure 2. Sample sizes are given in the upper-left
8 panel. Horizontal bars correspond to group-wise means. Violin plots and group means are not
9 shown for sample sizes $N \leq 5$. Markers on top of the x-axis denote a two-sample t-test between
10 $\epsilon 4$ carriers (ApoE variants $\epsilon 2/\epsilon 4$, $\epsilon 3/\epsilon 4$ and $\epsilon 4/\epsilon 4$) and $\epsilon 3$ homozygotes (ApoE genotype $\epsilon 3/\epsilon 3$;
11 n.s. = not significant; * $p < 0.05$).

12

13 **Figure 5 FADE and SAME scores by diagnostic group and amyloid positivity.** Single-value
14 fMRI scores are shown for (A) the FADE score and (B) the SAME score computed from the
15 novelty contrast as well as (C) the FADE score and (D) the SAME score computed from the
16 memory contrast. The layout follows that of Figure 2. Sample sizes are given in the upper-left
17 panel. Horizontal bars correspond to group-wise means. Violin plots and group means are not
18 shown for sample sizes $N \leq 5$. Markers on top of the x-axis denote a two-sample t-test between
19 Amyloid-positive ($A+$: $A\beta_{42/40} \leq 0.08$) and Amyloid-negative ($A-$: $A\beta_{42/40} > 0.08$)
20 individuals (n.s. = not significant; * $p < 0.05$).




Figure 1
114x152 mm (x DPI)

1
2
3
4




Figure 2
 135x89 mm (x DPI)




Figure 3
 114x38 mm (x DPI)

1
 2
 3
 4
 5
 6
 7




Figure 4
135x89 mm (x DPI)




Figure 5
135x89 mm (x DPI)

1
2
3
4

5
6
7
8

1 **Table 1 Demographic information of participant groups**

	HC	SCD	MCI	AD	AD-rel	Statistics
sample size	N = 128	N = 199	N = 74	N = 21	N = 46	–
age range	60–87 yrs	59–85 yrs	62–86 yrs	60–80 yrs	59–77 yrs	–
mean age	69.27 ± 5.48 yrs	70.36 ± 5.88 yrs	72.98 ± 5.13 yrs	72.56 ± 5.41 yrs	65.91 ± 4.69 yrs	$F_{4,463} = 13.50, p < 0.001$
test vs. HC	–	$t_{325} = 0.89, p = 0.372$	$t_{200} = 4.19, p < 0.001^{**}$	$t_{147} = 2.19, p = 0.030^*$	$t_{172} = -4.31, p < 0.001^{**}$	
gender ratio	48/80 m/f	109/90 m/f	35/39 m/f	8/13 m/f	18/28 m/f	$\chi^2_4 = 11.26, p = 0.024$
test vs. HC	–	$\chi^2_1 = 9.31, p = 0.002^{**}$	$\chi^2_1 = 1.86, p = 0.173$	$\chi^2_1 = 0.00, p = 0.958$	$\chi^2_1 = 0.04, p = 0.845$	
MMSE total	29.43 ± 0.87	29.17 ± 1.10	28.05 ± 1.56	24.52 ± 3.75	29.48 ± 0.89	$\chi^2_4 = 107.43, p < 0.001$
test vs. HC	–	$z = -2.20, p = 0.028^*$	$z = -7.24, p < 0.001^{**}$	$z = -7.20, p < 0.001^{**}$	$z = 0.46, p = 0.645$	
NPT global	0.47 ± 0.41	0.33 ± 0.56	-0.55 ± 0.56	-1.44 ± 0.75	0.53 ± 0.51	$F_{4,462} = 104.27, p < 0.001$
test vs. HC	–	$t_{324} = -2.49, p = 0.013^*$	$t_{200} = -14.91, p < 0.001^{**}$	$t_{147} = -17.32, p < 0.001^{**}$	$t_{172} = 0.80, p = 0.425$	
PACC5 score	0.20 ± 0.55	-0.08 ± 0.70	-1.34 ± 0.88	-3.31 ± 1.89	0.25 ± 0.77	$F_{4,448} = 106.78, p < 0.001$
test vs. HC	–	$t_{323} = -3.75, p < 0.001^{**}$	$t_{195} = -15.04, p < 0.001^{**}$	$t_{139} = -15.75, p < 0.001^{**}$	$t_{172} = 0.48, p = 0.628$	
Aβ 42/40 ratio	0.098 ± 0.021	0.096 ± 0.027	0.074 ± 0.030	0.049 ± 0.019	0.098 ± 0.027	$\chi^2_4 = 42.22, p < 0.001$
test vs. HC	–	$z = 0.32, p = 0.750$	$z = -3.70, p < 0.001^{**}$	$z = -5.05, p < 0.001^{**}$	$z = 0.86, p = 0.391$	
Amyloid positivity	10/41 A+/A- (77 missing)	29/63 A+/A- (117 missing)	26/17 A+/A- (31 missing)	13/1 A+/A- (7 missing)	5/19 A+/A- (22 missing)	$\chi^2_4 = 39.37, p < 0.001$
test vs. HC	–	$\chi^2_1 = 2.35, p = 0.125$	$\chi^2_1 = 16.48, p < 0.001^{**}$	$\chi^2_1 = 25.78, p < 0.001^{**}$	$\chi^2_1 = 0.02, p = 0.901$	

2 The Table shows multi-group comparisons (column “Statistics”) as well as pair-wise tests against healthy controls (rows “test vs. HC”).
3 Statistical inference was based on one-way ANOVAs and two-sample t-tests (age, NPT, PACC5), Kruskal-Wallis H-tests and Mann-Whitney U-
4 tests (MMSE, Aβ 42/40) or chi-square tests for independence (gender, Amyloid). HC = healthy controls, SCD = subjective cognitive decline,
5 MCI = mild cognitive impairment, AD = Alzheimer’s disease, AD-rel = AD relatives, N = sample size, yrs = years, m = male, f = female, MMSE
6 = Mini-Mental State Examination⁴⁵, NPT = neuropsychological testing⁴⁶, PACC5 = preclinical Alzheimer’s cognitive composite including the
7 categorical fluency measure⁴⁷, A+ = Amyloid-positive (Aβ 42/40 ≤ 0.08), A- = Amyloid-negative (Aβ 42/40 > 0.08)⁴⁸.

8 Significance: * $p < 0.05$.

9 ** Bonferroni-corrected for number of comparisons per variable (4).

10

11 **Table 2 Effects of site, gender and diagnosis on fMRI scores**

	novelty contrast: FADE score	novelty contrast: SAME score	memory contrast: FADE score	memory contrast: SAME score
main effect of site	$F = 2.36, p = 0.023$	$F = 1.95, p = 0.060$	$F = 1.46, p = 0.180$	$F = 1.91, p = 0.066$
main effect of gender	$F = 4.48, p = 0.035$	$F = 5.56, p = 0.019$	$F = 5.81, p = 0.016$	$F = 4.11, p = 0.043$
main effect of diagnosis	$F = 10.12, p < 0.001$	$F = 10.06, p < 0.001$	$F = 15.61, p < 0.001$	$F = 15.81, p < 0.001$
interaction of gender and diagnosis	$F = 1.05, p = 0.382$	$F = 1.17, p = 0.325$	$F = 0.04, p = 0.996$	$F = 1.47, p = 0.211$

12 Results from three-way ANOVA with acquisition site, participant gender and diagnosis group as factors, excluding interactions with the eight-
13 level factor site, for both scores (FADE, SAME) computed from both contrasts (novelty, memory). All F-values have 7 (site), 1 (gender), or 4
14 (diagnosis, interaction) numerator and 451 denominator degrees of freedom.

15

1 **Table 3 Comparison of ApoE genotypes to population distribution**

Group	$\epsilon 2/\epsilon 2$	$\epsilon 2/\epsilon 3$	$\epsilon 2/\epsilon 4$	$\epsilon 3/\epsilon 3$	$\epsilon 3/\epsilon 4$	$\epsilon 4/\epsilon 4$	Statistics
Population	0.60	12.46	2.81	59.80	22.21	2.11	–
HC (N = 125)	0.80	15.20	0.80	64.00	16.80	2.40	$\chi^2_2 = 1.78, p = 0.410$
SCD (N = 193)	1.04	11.92	2.59	54.40	27.98	2.07	$\chi^2_3 = 3.58, p = 0.310$
MCI (N = 73)	2.74	5.48	5.48	45.21	31.51	9.59	$\chi^2_2 = 11.26, p = 0.004$
AD (N = 21)	0.00	4.76	0.00	14.29	61.90	19.05	$\chi^2_1 = 36.59, p < 0.001$
AD-rel (N = 46)	0.00	6.52	2.17	63.04	23.91	4.35	$\chi^2_2 = 1.87, p = 0.393$

2 Relative frequencies for each genotype in percent (for absolute frequencies, see Supplementary Figure S4) and results of chi-squared goodness-
 3 of-fit tests for each participant group against an assumed population distribution⁶⁰.

ACCEPTED MANUSCRIPT